# US Primary Aldosteronism Market > US Primary Aldosteronism Market Research Report By Diagnosis (blood test, imaging) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.29% - **2024:** $ 345.09 Million - **2025:** $ 370.25 Million - **2035:** $ 748.12 Million - **Key Players:** AstraZeneca (GB), Boehringer Ingelheim (DE), Novartis (CH), Pfizer (US), Bristol-Myers Squibb (US), Sanofi (FR), Eli Lilly (US), Merck & Co. (US), Johnson & Johnson (US) **Report ID:** MRFR/Pharma/18474-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-primary-aldosteronism-market-20021 --- ## Market Summary ## **US Primary Aldosteronism Market Overview** As per MRFR analysis, the US Primary Aldosteronism Market Size was estimated at 258.3 (USD Million) in 2023. The US Primary Aldosteronism Market Industry is expected to grow from 330(USD Million) in 2024 to 740 (USD Million) by 2035. The US Primary Aldosteronism Market CAGR (growth rate) is expected to be around 7.618% during the forecast period (2025 - 2035). ### **Key US Primary Aldosteronism Market Trends Highlighted** The US Primary Aldosteronism Market is experiencing a notable shift driven by increased awareness and diagnosis of the condition. As healthcare providers focus on identifying diseases that lead to hypertension, more cases of primary aldosteronism are being detected. This has led to a greater demand for advanced diagnostic tools and treatment options tailored for this specific disorder. The growing emphasis on personalized medicine is a key market driver, with healthcare systems looking to provide targeted therapies that cater to individual patient needs. Opportunities in the US market can be captured by further investment in innovative treatment methods and technologies. There is a rising interest in developing new pharmacological therapies, including mineralocorticoid receptor antagonists, which show promise in treating primary aldosteronism effectively. Furthermore, as public health campaigns aim to educate the population about the risks associated with untreated hypertension and its links to primary aldosteronism, there is potential for increased screening and early intervention. In recent times, the trend of integrating telemedicine into patient care has gained traction in the US, particularly in follow-up consultations for patients with primary aldosteronism. This technology allows for efficient monitoring and management of patients, further enhancing treatment adherence and improving health outcomes. The ongoing research initiatives funded by governmental health bodies also suggest a commitment to better understand this endocrine disorder, indicating sustained growth and innovation in the US Primary Aldosteronism Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Primary Aldosteronism Market Drivers** ### **Rising Prevalence of Primary Aldosteronism** The US [Primary Aldosteronism Market](../../../reports/primary-aldosteronism-market-5522) Industry is experiencing growth driven by the increasing prevalence of primary aldosteronism in the population. According to the American Heart Association, nearly 10% of patients with hypertension may have primary aldosteronism, translating to approximately 6 million individuals in the United States. This surge in cases has propelled the demand for diagnostic tests and treatment options for this condition. Necessitating more comprehensive approaches to management, healthcare providers and pharmaceutical companies are investing in innovative treatment methods. The National Institutes of Health has also recognized primary aldosteronism as a significant factor influencing hypertension, frequently advocating for improved awareness and diagnostic protocols. As a result, more patients are being diagnosed and treated, contributing positively to the growth of the US Primary Aldosteronism Market. ### **Technological Advancements in Diagnostic Methods** Advancements in diagnostic technologies are significantly impacting the US Primary Aldosteronism Market Industry. Innovations such as enhanced blood tests and imaging technologies have made diagnosing primary aldosteronism more accurate and efficient. The American College of Cardiology has highlighted that the introduction of new non-invasive diagnostic tools has facilitated early detection, leading to timely treatment interventions. Data from healthcare research suggests that accuracy rates in diagnosing primary aldosteronism have improved by 30% with these new methods. This trend not only benefits patients but also encourages healthcare providers and pharmaceutical companies to focus on developing novel therapies, thereby promoting market growth. ### **Increased Research and Development Efforts** Investments in Research and Development (R&D) aimed at understanding primary aldosteronism are a key driver for the US Primary Aldosteronism Market Industry. Major pharmaceutical companies are channeling significant funding into R&D to develop effective medication and treatment options. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately $6 billion is allocated annually to study endocrine disorders, including primary aldosteronism. With the ongoing emphasis on precision medicine, these studies are crucial in identifying genetic factors and tailored therapies, which supports better outcomes for affected individuals and consequently enhances market viability. ### **Growing Awareness of Endocrine Disorders** Public awareness regarding endocrine disorders, including primary aldosteronism, is on the rise in the US. Organizations such as the Endocrine Society have been active in educating the public and healthcare professionals about the importance of diagnosing and treating hormonal imbalances. Recent surveys indicate a 25% increase in public knowledge of the symptoms associated with primary aldosteronism over the past five years. This increase in awareness not only helps in early diagnosis but also drives patients to seek medical help, thereby creating higher demand for treatments and diagnostic services in the US Primary Aldosteronism Market Industry. ## **US Primary Aldosteronism Market Segment Insights** ### **Primary Aldosteronism Market Diagnosis Insights** The Diagnosis segment of the US Primary Aldosteronism Market plays a crucial role in identifying and managing this condition effectively. As the market grows in response to increasing awareness and understanding of Primary Aldosteronism, there is an emphasis on various diagnostic methods, primarily blood tests and imaging techniques. Blood tests are vital for measuring aldosterone levels and the renin-angiotensin-aldosterone system, with timely and accurate results directly impacting treatment plans for patients. Imaging techniques, including computed tomography (CT) scans and magnetic resonance imaging (MRI), are significant for locating adrenal tumors, further influencing treatment decisions. The integration of innovative technologies is advancing diagnostic accuracy and efficiency, aligning with the broader trends in the healthcare industry toward personalized medicine. Furthermore, the push for early diagnosis is driven by the rising prevalence of hypertension and cardiovascular diseases in the US. As more individuals are screened and diagnosed, healthcare providers are likely to enhance their diagnostic capabilities, creating opportunities for growth within this segment. Moreover, the growing reliance on advanced imaging modalities is indicative of a shift towards improved patient outcomes, reinforcing the importance of this segment in the overall management of Primary Aldosteronism. Overall, the Diagnosis segment is integral to the US Primary Aldosteronism Market, ensuring that patients receive appropriate interventions based on accurate and timely assessments. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Primary Aldosteronism Market Key Players and Competitive Insights** The US Primary Aldosteronism Market has garnered significant attention in recent years due to the rising awareness of this condition and the increasing prevalence of hypertension associated with aldosterone excess. This market is characterized by a growing demand for diagnostic and therapeutic solutions, leading to heightened competition among key players. Companies are focusing on research and development efforts to introduce innovative therapies while navigating the regulatory landscape, which has become more conducive for the approval of new treatments. The competitive environment is further fueled by partnerships and collaborations aimed at enhancing product portfolios, improving market penetration, and ultimately, addressing the unmet medical needs in the management of Primary Aldosteronism within the United States. Merck and Co is established as a robust player in the US Primary Aldosteronism Market, bringing a strong research and development background that is crucial for addressing this complex condition. The company has leveraged its vast experience and expertise in the pharmaceutical sector to develop effective treatment options that meet the specific needs of patients with Primary Aldosteronism. Merck and Co's strengths lie in its comprehensive pipeline of innovative therapies, which are supported by rigorous clinical trials and data-driven approaches. The company's commitment to patient-centric solutions and its strategic collaborations have enabled it to maintain a significant market presence, fueling ongoing growth in this competitive landscape. On the other hand, Bristol Myers Squibb has made a notable impact in the US Primary Aldosteronism Market with its strong focus on specialized therapeutics. The company boasts a portfolio of key products that effectively address the challenges associated with this condition, while also promoting awareness and education regarding the complications of untreated aldosterone excess. Bristol Myers Squibb has a solid market presence driven by its investments in research and targeted therapies, which has helped the company foster relationships within the healthcare community. In addition to its impactful product offerings, Bristol Myers Squibb has pursued mergers and acquisitions strategically to expand its capabilities and enhance its competitive edge. This approach not only strengthens Bristol Myers Squibb's position but also contributes to the continuous evolution of treatment options available to patients, thereby solidifying its role in this niche market. ### **Key Companies in the US Primary Aldosteronism Market Include** ## **US Primary Aldosteronism Market Industry Developments** In the US Primary Aldosteronism Market, recent developments have focused on advancements in drug treatments and increased awareness regarding the condition. Companies like Merck and Co, Bristol Myers Squibb, AstraZeneca, and Novartis are actively working on Research and Development initiatives to enhance patient outcomes through innovative therapies. Notably, in October 2022, Merck announced progress in their aldosterone antagonist that shows promise in treating resistant hypertension associated with Primary Aldosteronism. Additionally, in March 2023, AstraZeneca launched a new campaign aimed at early diagnosis of Primary Aldosteronism, acknowledging the underdiagnosis of this condition in hypertensive patients. Furthermore, recent market analysis indicates a significant increase in the market valuation due to rising prevalence rates and effective treatment options. The market has been further bolstered by the emphasis on personalized medicine and the development of new diagnostic tools. In terms of mergers and acquisitions, no significant transactions involving the listed companies have been reported recently that pertain to Primary Aldosteronism. The ongoing collaborations and partnerships among these leading pharmaceutical firms signal a strong commitment to expanding their presence in this therapeutic area. ## **US Primary Aldosteronism Market Segmentation Insights** ### **Primary Aldosteronism Market Diagnosis Outlook** ## Market Drivers ### Increasing Incidence of Hypertension The rising incidence of hypertension in the US is a critical driver for the primary aldosteronism market. Studies indicate that approximately 30-40% of patients with hypertension may have primary aldosteronism, which often goes undiagnosed. As awareness of hypertension increases, healthcare providers are more likely to screen for underlying causes, including primary aldosteronism. This trend is expected to boost the demand for diagnostic tests and treatment options within the primary aldosteronism market. Furthermore, the prevalence of hypertension is projected to rise, with estimates suggesting that by 2030, nearly 50% of adults in the US will be affected. This growing patient population will likely necessitate more comprehensive management strategies, thereby driving market growth. ### Rising Demand for Personalized Medicine The rising demand for personalized medicine is reshaping the primary aldosteronism market. Patients increasingly seek tailored treatment options that consider their unique genetic and biochemical profiles. This trend is particularly relevant in the management of primary aldosteronism, where individual responses to treatment can vary significantly. Pharmaceutical companies are investing in research to develop targeted therapies that address the specific needs of patients with primary aldosteronism. As personalized medicine continues to gain traction, it is likely to enhance treatment efficacy and patient satisfaction, thereby propelling growth in the primary aldosteronism market. ### Increased Focus on Preventive Healthcare An increased focus on preventive healthcare is emerging as a significant driver for the primary aldosteronism market. As healthcare providers emphasize early detection and management of chronic conditions, screening for primary aldosteronism is becoming more common. Preventive strategies aim to reduce the long-term complications associated with untreated primary aldosteronism, such as cardiovascular diseases. This shift towards preventive care is supported by public health initiatives and educational campaigns that raise awareness about the importance of regular health check-ups. Consequently, the primary aldosteronism market is likely to benefit from this proactive approach, leading to higher rates of diagnosis and treatment. ### Technological Advancements in Diagnostic Tools Technological advancements in diagnostic tools are significantly influencing the primary aldosteronism market. Innovations such as improved imaging techniques and more sensitive hormonal assays have enhanced the ability to diagnose primary aldosteronism accurately. For instance, the introduction of non-invasive tests has made it easier for clinicians to identify patients at risk. The market for diagnostic devices is projected to grow at a CAGR of around 8% over the next five years, reflecting the increasing demand for efficient diagnostic solutions. As healthcare providers adopt these advanced technologies, the primary aldosteronism market is likely to expand, offering new opportunities for manufacturers and healthcare professionals alike. ### Growing Investment in Healthcare Infrastructure The growing investment in healthcare infrastructure in the US is a notable driver for the primary aldosteronism market. Increased funding for healthcare facilities and services has led to enhanced access to diagnostic and treatment options for patients. This investment is particularly evident in urban areas, where specialized clinics for endocrine disorders are emerging. As healthcare systems evolve, the integration of multidisciplinary approaches to manage conditions like primary aldosteronism becomes more feasible. The US government has allocated substantial resources to improve healthcare delivery, which is expected to facilitate better patient outcomes and drive the primary aldosteronism market forward. ## Future Outlook The [Primary Aldosteronism Market](https://www.marketresearchfuture.com/reports/primary-aldosteronism-market-5522) is projected to grow at a 7.29% CAGR from 2025 to 2035, driven by increasing awareness, improved diagnostic techniques, and innovative treatment options. **New opportunities:** - Development of targeted therapies for resistant hypertension - Expansion of telehealth services for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection By 2035, the primary aldosteronism market is expected to achieve substantial growth and innovation. ## Segment Insights ### By treatment type: Mineralocorticoid receptor antagonists (Largest) vs. Adrenalectomy (Fastest-Growing) In the segment of treatment types for the US primary aldosteronism market, Mineralocorticoid receptor antagonists occupy a significant share, leading the market due to their efficacy in managing the condition. Alongside this, Adrenalectomy has emerged rapidly, gaining traction among healthcare providers and patients alike for its potential to provide definitive treatment outcomes. Other treatment forms, such as potassium-sparing diuretics and calcium-channel blockers, contribute to the diverse landscape yet remain in the shadows of these leading modalities. The growth trends in the segment are primarily driven by an increasing awareness of primary aldosteronism and its treatment options among healthcare providers and patients. Advances in surgical techniques related to Adrenalectomy are boosting its appeal as a faster-growing option. Additionally, the rising incidence of hypertension linked with aldosteronism is propelling the market demand for effective pharmacological treatments, primarily the mineralocorticoid receptor antagonists, reinforcing their dominant position in the segment. Mineralocorticoid receptor antagonists (Dominant) vs. Adrenalectomy (Emerging) Mineralocorticoid receptor antagonists stand out as the dominant treatment modality for primary aldosteronism due to their capacity to effectively control symptoms and manage blood pressure. These agents are well-tolerated and have established themselves as a first-line pharmacological option. In contrast, Adrenalectomy, although newer in clinical popularity, is gaining momentum as an emerging surgical treatment. With its potential for curing the underlying causes of primary aldosteronism, it is quickly becoming a preferred choice for specific patient profiles. The growth of these two segments showcases a balance between established pharmacotherapy and innovative surgical intervention, capturing diverse patient preferences and clinical practices. ### By end-users: Hospitals (Largest) vs. Ambulatory Surgical Centres (Fastest-Growing) In the US primary aldosteronism market, the end-user segment is dominated by hospitals, which account for a substantial share due to their advanced diagnostic and treatment facilities. These institutions provide comprehensive care and have the infrastructure to manage complex cases, making them a preferred choice for patients diagnosed with primary aldosteronism. In contrast, ambulatory surgical centres are gaining traction, capitalizing on the trend towards outpatient surgical procedures and the preference for less invasive treatments, which allows for shorter recovery times and reduced overall healthcare costs. The growth trends within this segment are driven by an increasing awareness of primary aldosteronism and its implications for health. More healthcare providers are recognizing the importance of early diagnosis and treatment, leading to enhanced patient flow toward hospitals. However, ambulatory surgical centres are positioned well for expansion, as they align with the ongoing shift towards outpatient care. This shift is largely influenced by technological advancements in minimally invasive surgical techniques and patient convenience, positioning them as a vital player in the forthcoming years. Hospitals (Dominant) vs. Ambulatory Surgical Centres (Emerging) Hospitals in the US primary aldosteronism market hold a dominant position, offering comprehensive medical services, advanced diagnostics, and multidisciplinary teams that cater to the complexities associated with this condition. Their extensive resources and specialized staff enable them to manage severe cases effectively, making hospitals a favorable option for many patients. On the other hand, ambulatory surgical centres are emerging as vital alternatives, leveraging advancements in surgical techniques that allow for outpatient procedures. These centres focus on patient-centric care, providing timely services with shorter wait times, which attracts an increasing number of patients seeking convenience and efficiency. As healthcare evolves, both segments are likely to play significant roles in addressing the needs of individuals affected by primary aldosteronism. ## Competitive Benchmarking The primary aldosteronism market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AstraZeneca (GB), Novartis (CH), and Pfizer (US) are actively engaged in enhancing their product portfolios and expanding their market reach. AstraZeneca (GB) has positioned itself as a leader in the development of novel therapies, emphasizing research and development to address unmet medical needs. Meanwhile, Novartis (CH) appears to be focusing on strategic collaborations to bolster its pipeline, particularly in the realm of precision medicine. Pfizer (US), on the other hand, is leveraging its extensive distribution network to optimize access to its treatments, thereby enhancing its competitive edge in the market.The business tactics employed by these companies reflect a concerted effort to localize manufacturing and optimize supply chains, which are crucial in a moderately fragmented market. This competitive structure allows for a diverse range of products and services, yet the influence of major players remains pronounced. The collective strategies of these companies not only enhance their operational efficiencies but also contribute to a more resilient market environment, capable of adapting to evolving healthcare demands. In October AstraZeneca (GB) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of aldosterone antagonists. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available for patients suffering from primary aldosteronism. The significance of this partnership lies in its potential to bring innovative treatments to market more swiftly, thereby addressing critical gaps in current therapeutic offerings. In September Novartis (CH) launched a comprehensive patient support program aimed at improving adherence to treatment regimens for primary aldosteronism. This initiative not only underscores Novartis's commitment to patient-centric care but also positions the company as a proactive player in enhancing treatment outcomes. By focusing on patient education and support, Novartis is likely to strengthen its brand loyalty and market share in this niche segment. In August Pfizer (US) expanded its clinical trial program for a novel dual-action therapy targeting primary aldosteronism. This expansion is indicative of Pfizer's strategy to diversify its product offerings and capture a larger share of the market. The implications of this move are substantial, as it may lead to the introduction of groundbreaking therapies that could redefine treatment paradigms in the coming years. As of November the primary aldosteronism market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift is likely to redefine how companies position themselves in the market, ultimately benefiting patients through improved treatment options. ## Recent News & Developments In the US Primary Aldosteronism Market, recent developments have focused on advancements in drug treatments and increased awareness regarding the condition. Companies like Merck and Co, Bristol Myers Squibb, AstraZeneca, and Novartis are actively working on Research and Development initiatives to enhance patient outcomes through innovative therapies. Notably, in October 2022, Merck announced progress in their aldosterone antagonist that shows promise in treating resistant hypertension associated with Primary Aldosteronism. Additionally, in March 2023, AstraZeneca launched a new campaign aimed at early diagnosis of Primary Aldosteronism, acknowledging the underdiagnosis of this condition in hypertensive patients. Furthermore, recent market analysis indicates a significant increase in the market valuation due to rising prevalence rates and effective treatment options. The market has been further bolstered by the emphasis on personalized medicine and the development of new diagnostic tools. In terms of mergers and acquisitions, no significant transactions involving the listed companies have been reported recently that pertain to Primary Aldosteronism. The ongoing collaborations and partnerships among these leading pharmaceutical firms signal a strong commitment to expanding their presence in this therapeutic area. ## Report Scope | MARKET SIZE 2024 | 345.09(USD Million) | | --- | --- | | MARKET SIZE 2025 | 370.25(USD Million) | | MARKET SIZE 2035 | 748.12(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.29% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AstraZeneca (GB), Boehringer Ingelheim (DE), Novartis (CH), Pfizer (US), Bristol-Myers Squibb (US), Sanofi (FR), Eli Lilly (US), Merck & Co. (US), Johnson & Johnson (US) | | Segments Covered | treatment type, end-users | | Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the primary aldosteronism market. | | Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the primary aldosteronism market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation for primary aldosteronism in 2024?** A: The overall market valuation for primary aldosteronism was $345.09 Million in 2024. **Q: What is the projected market valuation for primary aldosteronism by 2035?** A: The projected market valuation for primary aldosteronism is $748.12 Million by 2035. **Q: What is the expected CAGR for the primary aldosteronism market during the forecast period 2025 - 2035?** A: The expected CAGR for the primary aldosteronism market during the forecast period 2025 - 2035 is 7.29%. **Q: Which companies are considered key players in the primary aldosteronism market?** A: Key players in the primary aldosteronism market include AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Bristol-Myers Squibb, Sanofi, Eli Lilly, Merck & Co., and Johnson & Johnson. **Q: What segment had the highest valuation in the primary aldosteronism market in 2024?** A: In 2024, the segment of mineralocorticoid receptor antagonists had the highest valuation at $50.0 Million to $110.0 Million. **Q: What is the valuation range for surgical aldosteronism treatment in 2024?** A: The valuation range for surgical aldosteronism treatment in 2024 was between $25.0 Million and $55.0 Million. **Q: How do ambulatory surgical centres compare to hospitals in terms of market valuation?** A: Ambulatory surgical centres had a valuation range of $34.51 Million to $75.0 Million, whereas hospitals had a significantly higher range of $172.55 Million to $370.0 Million. **Q: What is the projected growth for the non-surgical aldosteronism treatment segment by 2035?** A: The non-surgical aldosteronism treatment segment is expected to grow, with a valuation range projected between $30.0 Million and $70.0 Million by 2035. **Q: What is the valuation range for palliative care in the primary aldosteronism market?** A: The valuation range for palliative care in the primary aldosteronism market was between $15.09 Million and $38.12 Million in 2024. **Q: Which end-user segment is expected to have the highest valuation by 2035?** A: By 2035, hospitals are expected to maintain the highest valuation among end-user segments, projected between $172.55 Million and $370.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-primary-aldosteronism-market-20021*